Zepbound for sleep apnea: coverage, cost, and how to get it

Sources checked October 7, 2026. Links to other companies on this page are unpaid. Advertising disclosure.

Yes. Zepbound (tirzepatide) is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. It is a shot you take once a week, along with eating fewer calories and moving more. (FDA-approved label (opens in a new tab))

Two numbers do most of the work:

• An AHI of 15 or higher on a sleep study. AHI counts how many times an hour your breathing stops or gets shallow while you sleep.
• A BMI of 30 or higher. BMI is a number based on your height and weight.

Insurance can pay for it. That includes Medicare Part D plans. But each plan writes its own rules, and a diagnosis alone does not mean a yes.

If no plan pays, Lilly (the company that makes Zepbound) lists $299 for the starter dose. The 10 mg and 15 mg sleep apnea maintenance doses are $449 per 28-day supply under its self-pay offer, with eligibility and refill conditions. Their regular cash price is $699. See the prices and terms.

If you use a CPAP, keep using it. Starting Zepbound is not a reason to stop.

On this page: Who qualifies · Insurance · Medicare · Cost · How to get it · If you're denied · Does it work? · CPAP · Safety

Who qualifies for Zepbound for sleep apnea

The FDA approved Zepbound for sleep apnea on December 20, 2024. The approval is for adults who have both:

1. Moderate-to-severe obstructive sleep apnea (OSA), and
2. Obesity.

It is meant to be used with a lower-calorie diet and more physical activity. You do not need to have diabetes. (FDA announcement (opens in a new tab), label (opens in a new tab))

The sleep number: AHI

AHI stands for apnea-hypopnea index. An apnea is a pause in your breathing. A hypopnea is a stretch of shallow breathing. Your AHI is how many of these happen per hour of sleep. It comes from a sleep study.

The Zepbound trials only took people with an AHI of 15 or more. (label, section 14.2 (opens in a new tab))

A home sleep test may report REI, or respiratory event index, instead. Its calculation can differ from AHI. Ask your plan which measure it accepts and have your clinician interpret the report. (AASM diagnostic guideline (opens in a new tab))

The weight number: BMI

BMI stands for body mass index. Both insurance policies below require a BMI of 30 or more for a new sleep apnea request. This table shows where BMI reaches 30, with the weight rounded up to the next whole pound. (CDC adult BMI categories (opens in a new tab))

Not on the table? Here is the math: weight in pounds × 703 ÷ height in inches ÷ height in inches.

Example: 5 ft 10 in is 70 inches. At 240 lb, that is 240 × 703 ÷ 70 ÷ 70 = a BMI of 34.4.

Ask your clinician to document your height, weight, and BMI. Your plan may need those dated records.

If you're close but not a match

Hitting both numbers doesn't settle it. A clinician still has to decide Zepbound is safe for you. See side effects and who should not take it.

No sleep study yet? Start there

A sleep study establishes the diagnosis and severity needed for an OSA coverage request. If you haven't been tested, start with a clinician who can choose the right test.

For some adults, a home sleep test can do the job. A clinician decides if a home test is right for you, orders it, and reads the result. AASM recommends an in-lab study after a negative, inconclusive, or technically inadequate home test. Significant heart or lung disease and certain other conditions also favor in-lab testing. (AASM diagnostic guideline (opens in a new tab))

Before you pay for one, know three things:

• Your plan may be picky about the test. One policy we read wants a sleep study from the last 12 months. Don't assume a home test will be accepted. Ask your plan before you pay cash.
• The result may not meet the OSA criteria. A diagnosis of mild OSA is outside this approval. A negative or unclear home test needs clinical follow-up, rather than an assumption that you have no sleep apnea.
• A test is not a prescription. We have not checked whether the testing services we compare also prescribe Zepbound. Ask before you book if that matters to you.

The home tests we compare include $189 advertised tests and a $464.50 BlueSleep example: $215 for the test + $115 for the initial visit + $115 for the results visit + $19.50 shipping. That is our calculation from BlueSleep's fees (opens in a new tab) and shipping charge (opens in a new tab), not an all-inclusive quote. Lofta's page (opens in a new tab) shows both $189 and $149, and Sleep Doctor's page (opens in a new tab) gives conflicting descriptions of which consultations its $189 cash price includes. Confirm the full price before paying. Checked October 7, 2026.

Planning to use insurance? Read what to ask about testing costs and insurance first.

Diagnosed, but can't find your report?

HIPAA generally gives you the right to a copy of records held by a covered healthcare provider, including your sleep study. Ask the office that ordered it for the full report, not just a summary. (HHS: access to your health information (opens in a new tab))

Will insurance cover Zepbound for sleep apnea?

Some plans do. Both published policies below require prior authorization. That means your prescriber sends your records, and the plan checks them against its rules before it pays.

Here is why the sleep apnea approval matters. A plan can exclude weight-loss drugs yet cover Zepbound for sleep apnea under separate rules. Sleep apnea is a different reason to prescribe the same drug. One of the policies below makes exactly that distinction.

Three different people make three different calls:

1. Your clinician decides if Zepbound is right for you.
2. Your plan decides if it will pay.
3. Your pharmacy runs the exact prescription and tells you your price.

A yes from one is not a yes from the next.

Which door is yours?

If your plan uses CVS Caremark: Lilly's savings page (opens in a new tab) says coverage "has been restored" for Zepbound on select CVS Caremark drug lists. That is Lilly's statement, seen October 7, 2026. Check your own plan.

Do you have to try CPAP first? Two real plans, two answers

We read two published policies on October 7, 2026. Look how far apart they are. PAP means positive airway pressure; CPAP is one type of PAP.

These are selected criteria from two examples. They are not a complete approval checklist for your plan. A plan run by either company can use a different document.

The lesson: don't guess. Get your plan's written rules. The next section gives you the exact questions.

What to gather and what to ask

Pick who pays for your prescriptions and where you are in the process. You'll get a checklist of papers to pull together and two lists of questions, one for your plan or pharmacy and one for your clinician, ready to copy. Choose No diagnosis yet for evaluation and testing questions. You do not need all eight papers before asking for help.

An example. Say you're on a Medicare Advantage plan with drug coverage and your request was just turned down. You pick Medicare and I was denied. You tick three rows: your plan details, the plan's written rules, and the denial letter. The helper shows "3 of 8 gathered." It tells you your door is your Part D plan, not the $50 GLP-1 Bridge. Your plan questions now ask how your prescriber requests a formulary exception, which exact rule was not met, and what the deadline is.

The helper does not decide if you qualify or if your plan will pay. Only your clinician and your plan can do that.

Does Medicare cover Zepbound for sleep apnea?

Yes, it can. A Medicare Part D drug plan can cover Zepbound when it is prescribed for moderate-to-severe obstructive sleep apnea in an adult with obesity. Your plan decides if Zepbound is on its drug list, what prior authorization it needs, and what you pay. (CMS (opens in a new tab))

Part D is the drug part of Medicare. You have it through a stand-alone drug plan or through a Medicare Advantage plan with drug coverage. Original Medicare alone (Parts A and B) does not pay for this.

Medicare has two doors. Sleep apnea puts you in the first one.

You may have heard about a $50-a-month Medicare program for these drugs. It is real. It is called the Medicare GLP-1 Bridge. But it is for weight management only.

Sources: CMS, Medicare GLP-1 Bridge (opens in a new tab); CMS, information for Part D plans (opens in a new tab); Lilly (opens in a new tab).

What if your plan doesn't list Zepbound? The Bridge is still not your backup. CMS says a person with a Part D-coverable OSA diagnosis is not eligible for the Bridge, whether or not their plan covers the drug for that condition. Your plan must offer an exception process. Ask your prescriber about requesting a "formulary exception." That is a request for the plan to cover a drug that is not on its list; approval is not automatic. (CMS Part D rules (opens in a new tab), exceptions (opens in a new tab))

What would you pay on Medicare?

It depends on your plan. Plans set their own deductibles, tiers, and copays. But there is a hard ceiling. In 2026, you pay no more than $2,100 out of pocket for the year for drugs your Part D plan covers. This is one cap across your covered Part D drugs, not a separate cap for Zepbound. Premiums and noncovered cash purchases are outside it. After you reach the cap, covered Part D drugs cost you $0 for the rest of that calendar year. (Medicare drug costs (opens in a new tab))

Here is a rough picture. It uses the standard 2026 Part D design: the full $615 deductible, then you pay 25%. Assume you start in January with none of the deductible paid, fill only this covered drug, have no Extra Help or other payments toward your cap, and make all these fills in 2026. We priced the drug at a round $1,000 a fill so the math is easy to follow. Your plan's price for Zepbound may be higher or lower.

This is our math, not a quote. Ask your plan for your real price.

Four things that can help:

• Extra Help. This is a Medicare program that lowers drug costs for people with limited income. See if you qualify for Extra Help (opens in a new tab).
• Monthly payments. The Medicare Prescription Payment Plan (opens in a new tab) lets you spread covered drug costs over the calendar year. It does not lower the total, and starting late in the year leaves fewer months to pay. Ask your plan.
• Open enrollment. It runs October 15 to December 7 (opens in a new tab). If Zepbound for sleep apnea matters to you, check each plan's drug list and OSA rules before you pick coverage for January 1, 2027.
• A new year resets the count. The cap starts over each January 1. Medicare lists a $2,400 cap for 2027 (opens in a new tab).

If you pay Lilly's cash price instead, that money does not count toward your $2,100 cap.

Asking about weight management without a Part D-coverable diagnosis? The Bridge has its own eligibility, BMI, and health rules. A denied OSA request does not make you eligible. Medicare's page explains the distinction: Medicare and weight-loss drugs (opens in a new tab).

How much does Zepbound cost for sleep apnea?

Eligible people with commercial insurance that covers the single-dose pen may pay as little as $25 with Lilly's card. Paying cash at the 10 mg or 15 mg sleep apnea doses, LillyDirect lists $449 under its purchase offer, or $699 at the regular price. One supply at these prices lasts 28 days. Your product, payment route, and savings terms decide which price applies.

These are the prices and terms Lilly publishes, checked October 7, 2026. (Lilly savings page (opens in a new tab), LillyDirect products (opens in a new tab), full program terms (opens in a new tab))

Three things the price tags don't tell you

The $25 card has a ceiling. For a 28-day single-dose-pen prescription, it takes off up to $100. If your plan's copay is $60, you pay $25. If your copay is $200, you pay $100. These examples assume you meet the card terms and have enough savings left under its annual limit.

The $299 price is for the starter dose. You start at 2.5 mg and step up. The approved sleep apnea maintenance dose is 10 mg or 15 mg, picked by your prescriber. Budget from the maintenance price and its conditions, not the $299 starter price. The $449 offer can change or end.

52 weeks is 13 fills, not 12. Thirteen 28-day supplies cover 364 days. If all 13 qualified for an unchanged $449 price, the medicine would cost 13 × $449 = $5,837. In an illustrative first 52 weeks, if your prescriber used one 28-day supply at 2.5 mg, one at 5 mg, then 11 supplies at higher doses eligible for that offer, the arithmetic would be $299 + $399 + (11 × $449) = $5,637.

This is a budgeting scenario from today's published prices, not a quote for a calendar year or a promise of 2027 savings. A 365-day year extends beyond those 13 supplies. Lilly's KwikPen cards stop at 11 fills in a calendar year and expire December 31, 2026; their terms alone do not support 13 discounted fills in that year. The separate LillyDirect Journey purchase-offer terms do not specify a numerical annual fill limit. Ask which program applies and what any later fills will cost. Don't pick or change a dose to hit a price. That is your prescriber's call.

The 45-day rule is easy to miss

After the first qualifying higher-dose purchase, keeping the $449 offer requires buying the next refill within 45 days of when the previous prescription arrived. The rule is about the purchase date, not just when you ask your prescriber for a refill.

At 10 mg, three supplies at the regular $699 price total $2,097. Three qualifying $449 supplies total $1,347. That is $750 more for the same 84 days of medicine. These are price comparisons, not instructions to change your injection schedule. (Lilly's Journey terms (opens in a new tab))

If a refill is going to be late, call your prescriber and pharmacy. Don't skip or stretch doses to save money.

Costs around the drug

The prices above are for the medicine only. Also ask about:

• The sleep study, if you need one
• Visits with your prescriber
• Pen needles for the KwikPen, or syringes for vials. Lilly says these are sold separately
• A follow-up sleep study later
• Taxes or fees at checkout

LillyDirect marks Zepbound as HSA and FSA eligible, with eligibility varying by plan. Check your exact purchase program before using those funds: the separate KwikPen Self-Pay Savings Card terms prohibit reimbursement of your out-of-pocket purchase from a healthcare reimbursement account. Ask Lilly and your benefits administrator how those terms apply to the route you use. (LillyDirect (opens in a new tab), card terms (opens in a new tab))

Lilly's savings cards on that page end December 31, 2026, and the company can change its offers sooner. Check the current terms before each purchase.

How to get Zepbound for sleep apnea

Get your sleep study report, see a prescriber, check your plan, and let the prescriber's office send the request. Here are the five steps.

1. Get your sleep study report in your hands. You want the full report. It should show your AHI, the test date, the kind of test, and that your sleep apnea is obstructive. No test yet? Start with the test. Lost the report? Get a copy.

2. See a prescriber. Your primary care doctor, a sleep doctor, or an obesity medicine clinician can prescribe Zepbound. The American Academy of Sleep Medicine says a sleep physician can help decide if it fits you. (AASM statement (opens in a new tab)) Say why you're there: "I want to ask about Zepbound for my obstructive sleep apnea."

3. Call your plan before the prescription goes in. Use the questions for your plan. Ask for the rules in writing.

4. Let the prescriber's office send the request. They fill out the prior authorization. You can help by handing over your records and asking who tracks the answer. The diagnosis on the request has to match your real records. If someone online tells you how to "word it" to get approved, skip that advice.

5. Before your first fill, confirm three things. Which form you're getting (single-dose pen, KwikPen, or vial). Your real price at the pharmacy. And your follow-up plan, including the date your approval ends.

This can take more than one call and more than one visit. That is normal.

Don't have a clinician? Lilly offers a search tool for in-person sleep apnea care (opens in a new tab) and a page connecting readers with independent telehealth for sleep apnea (opens in a new tab). These are Lilly's resources, not our partners. A visit does not promise a prescription. Ask about state availability, the visit price, and whether the clinician handles Zepbound OSA requests before you book.

What to do if your plan says no

Read the denial letter and find the exact reason. Then fix that one thing. A missing paper, a drug that's off the list, and a flat exclusion each need a different move.

On Medicare? Your first appeal is called a redetermination. Medicare says you generally have 65 days from the date on the denial notice to ask for it. Your notice has the exact steps. If waiting could hurt your health, ask your prescriber about a fast appeal. (Medicare: appeals in a drug plan (opens in a new tab))

Other kinds of coverage have their own deadlines. Go by your denial letter.

Still no? Lilly's cash price may be an option. See costs. If it is out of reach, ask your clinician about covered sleep apnea treatments and how to keep your care going.

How well does Zepbound work for sleep apnea?

It helps a lot of people, and it does not fix everyone. In two 52-week trials, people on Zepbound averaged about 25 to 29 fewer breathing interruptions an hour. About 42% and 50% reached the combined endpoint of remission or mild OSA without excessive daytime sleepiness, as defined below.

Zepbound acts on GIP and GLP-1 receptors to reduce appetite and food intake. The FDA says the improvement in OSA is likely related to the resulting weight reduction. It does not hold your airway open the way CPAP does. (FDA approval announcement (opens in a new tab), NHLBI: how CPAP works (opens in a new tab))

What the trials found after one year

Sources: FDA-approved label, Table 9 (opens in a new tab); the study, Malhotra and others, New England Journal of Medicine, 2024 (opens in a new tab).

PAP includes CPAP. The Epworth scale measures daytime sleepiness; a score of 10 or less was the trial's cutoff. The combined endpoint does not mean that every symptom disappeared, establish a permanent cure, or show that PAP can be stopped. These are group results, not a forecast for one person.

How to read those numbers

• People started high. The average starting AHI was about 46 to 53. An average drop of 25 to 29 is big. It still leaves many people with sleep apnea.
• It is not a cure rate. Many people on Zepbound did not meet that combined endpoint after a year: 57.8% in Trial 1 and 49.8% in Trial 2.
• The PAP trial was tested with the mask off. People paused PAP for 7 days before the final sleep study, under the study team's watch. That is a research step. It is not advice for you.
• Everyone got coaching. All groups had help with diet and activity.
• Lilly paid for the trials. Participants were titrated to a maximum tolerated dose of 10 mg or 15 mg.
• Some groups were small. About 7 in 10 people were men. Too few were 65 or older to tell if older adults respond differently.

How long does it take?

The pivotal trials measured the main result after 52 weeks; that does not tell you the week you will feel better. The labeled starting dose is 2.5 mg once a week for four weeks, then 5 mg. Further increases are in 2.5 mg steps after at least four weeks at the current dose. The recommended sleep apnea maintenance doses are 10 mg and 15 mg, so week 13 is the earliest labeled schedule for reaching 10 mg from a new start. Your prescriber sets your dose and pace based on response and tolerability. (Label, sections 2.1–2.2 (opens in a new tab))

What happens if you stop?

The weight can come back. In a separate weight-management trial, people who switched to a dummy shot after 36 weeks on tirzepatide gained an average 14% relative to their weight at the switch over the next 52 weeks. That is not 14% of the weight they had lost, and this was not a study of OSA recurrence after stopping. The American Academy of Sleep Medicine says lasting weight loss is needed to maintain the sleep apnea benefit. (Label, Study 4 (opens in a new tab); AASM statement (opens in a new tab))

Who it may not help

The same group says Zepbound only helps sleep apnea that is tied to weight. If the shape of your jaw or airway is the cause, weight loss may not fix it. That is one more reason to bring a sleep clinician into the decision.

Can Zepbound replace CPAP?

Not on your own, and maybe not ever. If you already use CPAP or another prescribed sleep apnea treatment, continue it until your sleep clinician reassesses your care. Don't stop because you start Zepbound or feel better. Your clinician decides when repeat testing is appropriate.

Here is what we know:

• The label says the trials did not test when, or whether, it is right to stop CPAP.
• After a year on Zepbound, many people had not reached the trial's combined endpoint of remission or mild OSA without excessive daytime sleepiness.
• The American Academy of Sleep Medicine tells patients not to stop CPAP or other treatment without medical advice. It says follow-up visits and repeat sleep studies may be needed. (AASM patient fact sheet (opens in a new tab))
• The dose takes time to build. Ask your clinician how your sleep apnea will be managed while the dose is increased and your response is assessed.

A good question for your clinician: "How will we watch my sleep apnea while I'm on Zepbound, and what would you need to see before we change my CPAP?"

Need a machine now, or a new one? You can compare CPAP buying options.

Side effects and who should not take it

Digestive side effects are common. Nausea, vomiting, and diarrhea occurred most often while the dose was increasing and generally decreased over time. Zepbound also carries a boxed warning about thyroid tumors. That warning comes from studies in rats. It is not known if Zepbound causes these tumors in people. (Current label, sections 5–6 (opens in a new tab))

Do not use Zepbound if:

• You or anyone in your family has had a thyroid cancer called medullary thyroid carcinoma (MTC)
• You have a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• You have had a serious allergic reaction to tirzepatide or anything in Zepbound

Tell your prescriber if you:

• Have had problems with your pancreas or gallbladder
• Have a stomach that empties slowly (gastroparesis) or serious trouble digesting food. Zepbound is not recommended for severe gastroparesis
• Have diabetic eye disease, or take insulin or a sulfonylurea. Those medicines can increase the risk of low blood sugar when used with Zepbound
• Are pregnant, plan to be, or are breastfeeding
• Have surgery or any procedure with anesthesia coming up
• Take birth control pills. The label advises switching to a nonoral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase; discuss this with your prescriber
• Take any other tirzepatide or GLP-1 medicine. They should not be used together

If pregnancy occurs, contact your prescriber promptly. The label directs stopping Zepbound when pregnancy is recognized.

The most common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn.

Stop Zepbound and get medical help right away if you have:

• Severe stomach pain that will not go away, with or without vomiting
• Swelling of your face, lips, tongue, or throat
• Trouble breathing or swallowing, a severe rash, or fainting

Call your prescriber right away for vomiting or diarrhea that will not stop. Losing too much fluid can hurt your kidneys.

This is a short summary, not the full list. Read the Zepbound Medication Guide (PDF) (opens in a new tab), revised August 2026, and ask your prescriber or pharmacist about anything that worries you.

Staying covered: renewals

Getting approved is not the finish line. An approval can expire, and the plan can ask for updated records before it renews.

Both policies we read give a first approval of 6 months. What they want next is different. CVS Caremark asks for achieved or maintained symptom improvement and a maintenance dose. Centene's first renewal asks for at least 5% weight loss plus improvement in AHI, sleep-apnea hypoxic burden, or a listed patient-reported sleep score. That first renewal lasts 6 months; its later renewals have different response criteria and can last 12 months. Read the full policy for the other requirements.

Do three things now so renewal is easy later:

1. Write down the date your approval ends.
2. Ask your plan what it needs to renew: symptoms, weight, a new sleep study, CPAP records.
3. Keep your first sleep study report and your starting weight. Plans compare against them.

Good news can raise questions too. If your BMI drops under 30, or your sleep apnea improves, ask your plan how it counts that. Don't assume it ends your coverage. Don't assume it can't.

Switching plans? Ask the new plan if it will treat you as a new start or as someone already on treatment.

More questions

Is Mounjaro approved for sleep apnea?

No. Mounjaro has the same active drug as Zepbound, tirzepatide. Its FDA-approved label (opens in a new tab) does not include an OSA indication. Its indications concern type 2 diabetes.

Does the approval cover other weight-loss shots or compounded tirzepatide?

No. The sleep apnea approval belongs to Zepbound. Don't assume another drug has the same approval or the same coverage rules. The FDA says compounded drugs are not FDA-approved. (FDA (opens in a new tab)) Ask your prescriber and pharmacist exactly which medicine you're getting.

Will insurance pay for both CPAP and Zepbound?

It can. CPAP is equipment. Zepbound is a pharmacy drug. On Medicare, for example, eligible CPAP therapy falls under Part B (opens in a new tab), while this prescription follows Part D rules. Some plans even require CPAP use before they'll pay for Zepbound. Ask about each one.

My CPAP machine shows a low AHI. Is that my AHI now?

That is the machine's estimate while you are using PAP, not your untreated diagnostic AHI. A low number can be reassuring, but it does not by itself show that your sleep apnea has resolved or explain ongoing symptoms. Ask which diagnostic and treatment records your plan needs. Do not stop PAP based on the machine number. (AASM follow-up guidance (opens in a new tab))

How we checked this page

We read the sources ourselves on October 7, 2026:

• The FDA-approved Zepbound label and Medication Guide, both revised August 2026
• CMS and Medicare pages on Part D and the Medicare GLP-1 Bridge
• Lilly's published prices and savings terms
• Two insurer policies, named and linked above
• Statements and fact sheets from the American Academy of Sleep Medicine

Prices and plan rules change. Each one above shows where it came from so you can check it.

What we did not do: no clinician has reviewed this page. We did not contact any plan, test any service, or check anyone's benefits. We don't read sleep study reports or tell you what treatment to choose. Your clinician, your plan, and your pharmacy make those calls.

See something out of date? Send us the source. Please don't send medical or insurance records.

More on how we work: editorial standards and how we compare.